The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Well i emailed jamie on tuesday,but as yet no reply.i'm disappointed as he has alway replied before,even if only to say he can't really add anything etc.of course there is a multiplicity of reasons why he might not have replied and im not 100% certain that his correct email is still as it was in the regent pacific days,but it looks as though it is based on the change of name back to regent announcement etc. anyway,I've had no bounce back, so im assuming it was received.i will evaluate whether to send a chaser after the weekend.
Yes ,the lock in period is a positive.in the event of a T/O before the exercise cut off there will doubtless be provisions to compensate etc. i really don't see anything unreasonable or untoward here at all.
£265k trade @53p earlier today.from s/p movement im guessing it was a buy. "o"trade.
Personally i don't have problem with the awards, as i think it aligns the directors' interests more closely with those of the company. my only qualification would be that the exercise price is pretty low, so slightly disappointed in that.
Dougie,i will email jamie tomorrow if no news in the morning(grandparents day today,so not much time)
Morning dosanddonts. fair point. let us hope they have learned from previous experiences.
It's true that they have got other products to market before, but i donot think any of them have had the partnerships and distribution backing which this has . imo it is of a completely different order.
Mickey mouse? really!
Clever,but depressing!
25th oct last year.no prior warning.
Very much doubt it,DRM72. the agreement with haleon gives them the right exclusively to commercialise the distribution of eroxon in the us.i assume it it is some form of opportunistic exercise by persons unrelated to fum.
Quite correct,fatherelmer.no problem in principle getting over the nominal value issue. ive been in a number of companies which have had to do it.
Under the original co-high licensing agreement riverwood high growth fund received certain convertible loan note and warrants.i won't recite the precise details of what they did with them,but the last relaible information we had was the RNS of 4/5/21 stating they had reduced their holding from 3.102% to 2.73%, totalling 7m shares. they may well have reduced further since then as the deal fell through and it would be a reasonable assumption to suggest they would sell down further following its failure. it is ,however,merely an assumption and nothing more.as they were below 3% in may 21,we will have had no statements of any dealings below that level. in case you are not clear, co-high was the licensee,but the shares were held by riverwood. both co high and riverwood are in effect owned by atlantis.
Thanks very much for that, trousers, appreciated. looks like we will know the options reasonably soon.
Interesting,1pencil.small in itself,but i think it serves to remind us of the potential benefit of a move to premium listing (or the amalgamation if that is the way it goes.) i think someone posted earlier questioning why any institutions would buy in at this point.well if we go premium,the trackers will have no choice,and i personally think this potential effect on a company with a fairly small free float is being greatly underestimated.
Ok dougie.i will leave it until next week,but if nothing by then i will email.obviously he won't say anything price sensitive,but he might just indicate the news is coming shortly,or something of that nature.he has always replied in fairness.
Agreed .really frustrating.i did toy with the idea of emiling jamie, but probably no point.
Or perhaps regent simply inhabits a parallel universe with its own time frame? who knows with this lot!.morning bignose.
Excellent news.futura have significant experience in patent applications, so im not surprised, but extremely good news to have this confirmed.